Cencora revises forecast for 2026, approves $2 billion share buyback

U.S. drug distributor Cencora on Thursday raised the lower end of its fiscal ​2026 earnings forecast citing recent ‌share repurchases, and also approved a new $2 billion stock buyback plan.